Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Phase: Phase 1"
topic_facet:"Medical Condition: The ‘wet’ form of age-related macular degeneration (AMD) is a disease which affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by choroidal neovascularisation (the abnormal growth of blood vessels under the macula), which may leak fluid and blood and cause swelling (Eylea SmPC) MedDRA version: 20.0Level: LLTClassification code 10075568Term: Wet age-related macular degenerationSystem Organ Class: 100000004853;Therapeutic area: Diseases [C] - Eye Diseases [C11]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+The+%E2%80%98wet%E2%80%99+form+of+age-related+macular+degeneration+%28AMD%29+is+a+disease+which+affects+the+central+part+of+the+retina+%28called+the+macula%29+at+the+back+of+the+eye.+The+wet+form+of+AMD+is+caused+by+choroidal+neovascularisation+%28the+abnormal+growth+of+blood+vessels+under+the+macula%29%2C+which+may+leak+fluid+and+blood+and+cause+swelling+%28Eylea+SmPC%29+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10075568Term%3A+Wet+age-related+macular+degenerationSystem+Organ+Class%3A+100000004853%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Eye+Diseases+%5BC11%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+The+%E2%80%98wet%E2%80%99+form+of+age-related+macular+degeneration+%28AMD%29+is+a+disease+which+affects+the+central+part+of+the+retina+%28called+the+macula%29+at+the+back+of+the+eye.+The+wet+form+of+AMD+is+caused+by+choroidal+neovascularisation+%28the+abnormal+growth+of+blood+vessels+under+the+macula%29%2C+which+may+leak+fluid+and+blood+and+cause+swelling+%28Eylea+SmPC%29+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10075568Term%3A+Wet+age-related+macular+degenerationSystem+Organ+Class%3A+100000004853%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Eye+Diseases+%5BC11%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Phase%3A+Phase+1%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+The+%E2%80%98wet%E2%80%99+form+of+age-related+macular+degeneration+%28AMD%29+is+a+disease+which+affects+the+central+part+of+the+retina+%28called+the+macula%29+at+the+back+of+the+eye.+The+wet+form+of+AMD+is+caused+by+choroidal+neovascularisation+%28the+abnormal+growth+of+blood+vessels+under+the+macula%29%2C+which+may+leak+fluid+and+blood+and+cause+swelling+%28Eylea+SmPC%29+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10075568Term%3A+Wet+age-related+macular+degenerationSystem+Organ+Class%3A+100000004853%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Eye+Diseases+%5BC11%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
PubPharm (14)
1
The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator : A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration - MYLIGHT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
2
The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator : A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration - MYLIGHT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
3
The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator : A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration - MYLIGHT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator : A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration - MYLIGHT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator : A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration - MYLIGHT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator : A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration - MYLIGHT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
7
The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator : A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration - MYLIGHT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator : A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration - MYLIGHT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator : A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration - MYLIGHT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
10
The study is investigating the use of an investigational medication (SOK583A1, a proposed biosimilar medicine to Eylea®) in wet AMD patients. The aim of study is to demonstrate similar safety and efficacy of the proposed biosimilar to the originator : A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular age-related macular degeneration - MYLIGHT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Phase: Phase 1
Filter aufheben
Thema: Medical Condition: The ‘wet’ form of age-related macular degeneration (AMD) is a disease which affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by choroidal neovascularisation (the abnormal growth of blood vessels under the macula), which may leak fluid and blood and cause swelling (Eylea SmPC) MedDRA version: 20.0Level: LLTClassification code 10075568Term: Wet age-related macular degenerationSystem Organ Class: 100000004853;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Medienart
14
Aufsätze
14
E-Artikel
14
E-Ressourcen
Zeitschriftentitel
14
WHO International Clinical Trials Registry Plat...
Thema
14
610
Medical Condition: The ‘wet’ form of age-re...
Phase: Phase 1
14
Recruitment Status: Authorised-recruitment may ...
14
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
8
2022
6
2021
Erscheinungsjahr(e)
Von:
Bis:
Sprache
14
Englisch
Haven't found what you're looking for?
Wird geladen...